Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report
- PMID: 31660392
- PMCID: PMC6736362
- DOI: 10.1093/ofid/ofz235
Left Ventricular Assist Device Infections and the Potential Role for Dalbavancin: A Case Report
Abstract
Left ventricular assist device infections (LVADIs) are common but challenging to treat, often requiring prolonged courses of intravenous antibiotics. Dalbavancin could have a role in treating patients with chronic LVADIs given its less frequent dosing requirements. Here, we illustrate a case in which dalbavancin was used as suppressive therapy for an LVADI for greater than 7 months.
Keywords: Staphylococcus aureus; dalbavancin; left ventricular assist devices.
© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures
References
-
- McCarthy FH, Kobrin D, Rame JE, et al. . Increasing frequency of left ventricular assist device exchanges in the United States. Ann Thorac Surg 2015; 100:1660–4; discussion 1665. - PubMed
-
- Pfaller MA, Mendes RE, Duncan LR, et al. . Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015-16. J Antimicrob Chemother 2018; 73:2748–56. - PubMed
-
- Boucher HW, Wilcox M, Talbot GH, et al. . Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 2014; 370:2169–79. - PubMed
